Metatron Long Term Equity Fund’s Halozyme HALO Stock Holding History

Metatron Long Term Equity Fund’s Portfolio HALO Stock Details HALO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.66M	Buy	+34,000	New	+$2.32M	1.21%	25

Other funds holding HALO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Metatron Long Term Equity Fund's HALO Position: Q2 2026 in Review

Metatron Long Term Equity Fund opened a new position in Halozyme (HALO) in Q2 2026: 34,000 shares worth $2.66M. The stake represents 1.21% of the portfolio and ranks #25 among its holdings.

664 funds tracked by Wall St. Rank hold HALO as of Q2 2026.

Metatron Long Term Equity Fund held 34,000 shares of Halozyme worth $2.66M as of Q2 2026.
Halozyme was a new Metatron Long Term Equity Fund position in Q2 2026.
Halozyme made up 1.21% of Metatron Long Term Equity Fund's portfolio in Q2 2026, its #25 holding.
664 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.

Based on Metatron Long Term Equity Fund's 13F filing for Q2 2026, filed 29 Jul 2026.